Pulse Biosciences Statistics
Share Statistics
Pulse Biosciences has 61.52M shares outstanding. The number of shares has increased by 11.27% in one year.
| Shares Outstanding | 61.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 10.98% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.26M |
| Failed to Deliver (FTD) Shares | 922 |
| FTD / Avg. Volume | 0.55% |
Short Selling Information
The latest short interest is 2.54M, so 4.12% of the outstanding shares have been sold short.
| Short Interest | 2.54M |
| Short % of Shares Out | 4.12% |
| Short % of Float | 14.84% |
| Short Ratio (days to cover) | 21.18 |
Valuation Ratios
The PE ratio is -13.93 and the forward PE ratio is -19.71.
| PE Ratio | -13.93 |
| Forward PE | -19.71 |
| PS Ratio | 0 |
| Forward PS | 46.4 |
| PB Ratio | 13.25 |
| P/FCF Ratio | -17.73 |
| PEG Ratio | n/a |
Enterprise Valuation
Pulse Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 6.76, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.76 |
| Quick Ratio | 6.76 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.33 |
| Cash Flow / Debt | -31.23 |
| Interest Coverage | -31.95 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -81.44%.
| Return on Equity (ROE) | -0.95% |
| Return on Assets (ROA) | -0.71% |
| Return on Capital (ROIC) | -81.44% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -753.75K |
| Employee Count | 56 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 79.07% in the last 52 weeks. The beta is 1.75, so Pulse Biosciences 's price volatility has been higher than the market average.
| Beta | 1.75 |
| 52-Week Price Change | 79.07% |
| 50-Day Moving Average | 17.56 |
| 200-Day Moving Average | 13.98 |
| Relative Strength Index (RSI) | 44.84 |
| Average Volume (20 Days) | 166.72K |
Income Statement
In the last 12 months, Pulse Biosciences had revenue of $0 and earned -$42.21M in profits. Earnings per share was $-0.88.
| Revenue | 0 |
| Gross Profit | -1.21M |
| Operating Income | -43.57M |
| Net Income | -42.21M |
| EBITDA | -42.37M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.88 |
Balance Sheet
The company has $44.37M in cash and $9.14M in debt, giving a net cash position of $35.22M.
| Cash & Cash Equivalents | 44.37M |
| Total Debt | 9.14M |
| Net Cash | 35.22M |
| Retained Earnings | -336.92M |
| Total Assets | 93.05M |
| Working Capital | 73.67M |
Cash Flow
In the last 12 months, operating cash flow was -$33.04M and capital expenditures -$121.00K, giving a free cash flow of -$33.16M.
| Operating Cash Flow | -33.04M |
| Capital Expenditures | -121.00K |
| Free Cash Flow | -33.16M |
| FCF Per Share | -0.69 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PLSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.99% |
| FCF Yield | -3.06% |
Analyst Forecast
Currently there are no analyst rating for PLSE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 39.13 |
| Piotroski F-Score | 3 |